Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Paladin Labs Inc. Announces Research and Development Contribution from the National Research Council of Canada Industrial Research Assistance Program for its ChimigenŽ Platform

Abstract:
Paladin Labs Inc. (TSX:PLB), a leading Canadian specialty pharmaceutical company, announced today that its biotechnology division, ViRexx, has received a contribution from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP). This 14-month project will focus on the development of bio-nanoparticle-based siRNA therapeutic vaccines using ChimigenŽ Vaccine Platform for Hepatitis B (HBV) and Hepatitis C (HCV) infections.

Paladin Labs Inc. Announces Research and Development Contribution from the National Research Council of Canada Industrial Research Assistance Program for its ChimigenŽ Platform

Montreal, QC, Canada and Edmonton, AB, Canada | Posted on July 17th, 2009

"We are pleased to be working with NRC to further develop this promising technology, and the financial support, in addition to both technical and business oriented advisory services, from NRC-IRAP will accelerate the development of ViRexx's proprietary ChimigenŽ Platform for multiple uses in the field of infectious diseases," commented Dr. Rajan George, the Chief Technology Officer of ViRexx.

ViRexx is currently developing a ChimigenŽ HBV Therapeutic Vaccine to address the 370 million chronic carriers of Hepatitis B virus worldwide, who are poorly served by existing therapies. ViRexx is also developing ChimigenŽ HCV Therapeutic vaccines, as well as bio-nanoparticle-based siRNA therapeutic vaccines for both HBV and HCV infections.

"The acquisition of ViRexx gave us a very promising technology in ChimigenŽ Platform. We are excited to be working with NRC-IRAP on the development of this important technology platform", added Jonathan Ross Goodman, President and CEO of Paladin Labs Inc.

####

About Paladin Labs Inc.
Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market. With this strategy, a focused national sales team and proven marketing expertise, Paladin has evolved into one of Canada's leading specialty pharmaceutical companies. Paladin's shares trade on the Toronto Stock Exchange under the symbol PLB. For more information about Paladin, please visit the Company's web site at www.paladinlabs.com.

About ViRexx

ViRexx, a division of Paladin Labs Inc., develops innovative targeted therapeutics for individuals that suffer from infectious diseases and cancer. Using its ChimigenŽ Platform Technology, ViRexx has developed a portfolio of biotherapeutic agents to meet major unmet medical needs such as treatments for chronic hepatitis B and hepatitis C virus infections, avian influenza, alphavirus infections and cancer. ViRexx is also developing this technology for targeted siRNA delivery.

This press release may contain forward-looking statements and predictions. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions that these assumptions regarding the future events, many of which are beyond the control of the Company and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations, are discussed in the annual report as well as in the Company's Annual Information Form for the year ended December 31, 2008. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events and except as required by law. For additional information on risks and uncertainties relating to these forward-looking statements, investors should consult the Company's ongoing quarterly fillings, annual report and Annual Information Form and other fillings found on SEDAR at www.sedar.com.

For more information, please click here

Contacts:
Paladin Labs Inc.
Samira Sakhia
Chief Financial Officer
514-669-5367
514-344-4675 (FAX)

Copyright © Marketwire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Northwestern researchers achieve unprecedented control of polymer grids: Materials could find applications in water purification, solar energy storage, body armor June 22nd, 2018

Nanobiotix Publishes Positive Phase 2/3 Data For Nanomedicine in Soft Tissue Cancer (Webcast June 22) June 22nd, 2018

Alzheimer's breakthrough: Brain metals that may drive disease progression revealed: In brains affected by Alzheimer's, researchers identify chemically reduced iron species, with mineral forms including a magnetic iron oxide June 22nd, 2018

Collaboration yields discovery of 12-sided silica cages June 20th, 2018

Govt.-Legislation/Regulation/Funding/Policy

Nanobiotix Publishes Positive Phase 2/3 Data For Nanomedicine in Soft Tissue Cancer (Webcast June 22) June 22nd, 2018

Alzheimer's breakthrough: Brain metals that may drive disease progression revealed: In brains affected by Alzheimer's, researchers identify chemically reduced iron species, with mineral forms including a magnetic iron oxide June 22nd, 2018

Collaboration yields discovery of 12-sided silica cages June 20th, 2018

Powering the 21st Century with Integrated Photonics: UCSB-Led Team Selected for Demonstration of a Novel Waveguide Platform Which is Transparent Throughout the MWIR and LWIR Spectral Bands June 19th, 2018

Nanomedicine

Nanobiotix Publishes Positive Phase 2/3 Data For Nanomedicine in Soft Tissue Cancer (Webcast June 22) June 22nd, 2018

Alzheimer's breakthrough: Brain metals that may drive disease progression revealed: In brains affected by Alzheimer's, researchers identify chemically reduced iron species, with mineral forms including a magnetic iron oxide June 22nd, 2018

Collaboration yields discovery of 12-sided silica cages June 20th, 2018

JPK talks with Dr Frank Lafont, Director of the BioImaging Center Lille (BICeL) about the use of the NanoWizardŽ AFM together with fluorescence microscopy in the study of living cells June 19th, 2018

Announcements

Northwestern researchers achieve unprecedented control of polymer grids: Materials could find applications in water purification, solar energy storage, body armor June 22nd, 2018

Nanobiotix Publishes Positive Phase 2/3 Data For Nanomedicine in Soft Tissue Cancer (Webcast June 22) June 22nd, 2018

Alzheimer's breakthrough: Brain metals that may drive disease progression revealed: In brains affected by Alzheimer's, researchers identify chemically reduced iron species, with mineral forms including a magnetic iron oxide June 22nd, 2018

Collaboration yields discovery of 12-sided silica cages June 20th, 2018

Grants/Sponsored Research/Awards/Scholarships/Gifts/Contests/Honors/Records

Northwestern researchers achieve unprecedented control of polymer grids: Materials could find applications in water purification, solar energy storage, body armor June 22nd, 2018

Alzheimer's breakthrough: Brain metals that may drive disease progression revealed: In brains affected by Alzheimer's, researchers identify chemically reduced iron species, with mineral forms including a magnetic iron oxide June 22nd, 2018

Collaboration yields discovery of 12-sided silica cages June 20th, 2018

Squeezing light at the nanoscale: Ultra-confined light could detect harmful molecules June 17th, 2018

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project